Diagnosis of Latent Tuberculosis in Patients with Systemic Lupus Erythematosus: T.SPOT.TB versus Tuberculin Skin Test

Table 5

T.SPOT.TB positive versus T.SPOT.TB negative patients. Univariate analyses.

Clinical and laboratory findings	T.SPOT positive (𝑛=5)	T.SPOT negative; (𝑛=87)	𝑃 value
Age, years, mean ± SD	62.40±12.75	41.57±14.25	0.002
Patients with risk factors for LTBI, 𝑛 (%)	1 (20)	8 (9.2)	0.41
SLE disease duration SLE, median (IQR)	174 (135–357)	126 (60–207)	0.10
SLEDAI, mean ± SD	2.4±2.5	3.39±2.75	0.43
SLICC, median (IQR)	0 (0–0.75)	0 (0-1)	0.53
dsDNAn, UI/mL, median (IQR)	13.70 (2.05–33)	14.50 (3.72–45.50)	0.65
Daily prednisone > 7.5 mg, 𝑛 (%)	1 (20)	17 (19.5)	0.53
Immunosuppressed patients, 𝑛 (%)	2 (40)	57 (65.5)	0.56
Hydroxychloroquine treatment, 𝑛 (%)	4 (80)	75 (86.2)	0.54
Steroid dose, mg, mean ± SD	3±4.47	3.93±4.89	0.67
Steroid cumulative dose, mg, mean ± SD	18486±18460.34	17895.22±22196.28	0.94
Cumulative steroids/duration of disease, mg/year, mean ± SD	1076.41±1099.36	1636.42±1454.14	0.40
Mycophenolate dose, mg, mean ± SD	216±482.99	252.06±529.19	0.88
Mycophenolate cumulative dose, mg, mean ± SD	4800±10733.12	636067.81±1324014	0.001
Cumulative mycophenolate/disease duration, mg/year, mean ± SD	23.52±52.61	76100.72±160264.94	0.001
Methotrexate dose, mg, mean ± SD	0	1.29±3.32	0.38
Methotrexate cumulative dose, mg, mean ± SD	216±482.99	320.69±794	0.77
Cumulative methotrexate/disease duration, mg/year, mean ± SD	1.05±2.36	48.72±131.88	0.42